Aimwell Partners Inc. Publishes the Adversarial Validation Standard, v1, an Open Methodology Framework for Verifying AI-Generated Biopharma Intelligence
By financialcontent · Source: financialcontent · 2026-07-01
MIAMI, FL / ACCESS Newswire / July 1, 2026 / Aimwell Partners Inc. (OTCID:AIMN) ("Aimwell" or the "Company"), the parent company of AimwellBio, today announced the publication of the Adversarial Validation Standard, v1, a versioned, open methodology framework designed to establish a transparent reference for decision integrity in AI-generated biopharmaceutical intelligence.
ONLY AVAILABLE IN PAID PLANS